As more couples in India turn to assisted reproduction to build families, the country's leading fertility and embryology bodies have flagged a test marketed as a way to assess the genetic health of embryos without touching or biopsying them, saying it should not be used for routine clinical use due to high rates of misdiagnosis. The technique referred to is non-invasive preimplantation genetic testing (niPGT), also called non-invasive chromosomal screening (NICS). In a first-of-its-kind patient-focused initiative, the Indian Society for Assisted Reproduction (ISAR), the Indian Fertility Society (IFS), and the Academy of Clinical Embryologists (ACE) jointly evaluated niPGT to determine whether it is truly ready for clinical use. The exercise was led by scientist Dr Deepak Modi at the Indian Council of Medical Research-?National Institute for Research in Reproductive and Child Health (ICMR-NIRRCH). After a detailed review of global evidence, the experts concluded that niPGT is not ye